Scottish and Newcastle Anti-emetic Pre-treatment for Paracetamol Poisoning Study
To assess the effectiveness of pre-treatment with ondansetron at reducing nausea and vomiting in patients treated with either the conventional regimen or a modified regimen of acetylcysteine for paracetamol Poisoning
Multi centre randomised controlled trial of ondansetron vs placebo in patients treated with either the conventional regimen or a modified regimen of Acetylcysteine for Paracetamol Poisoning
Antoine DJ, Dear JW, Lewis PS, Platt V, Coyle J, Masson M, Thanacoody RH, Gray AJ, Webb DJ, Moggs JG, Bateman DN, Goldring CE, Park BK. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology. 2013 Aug; 58(2):777-87. doi: 10.1002/hep.26294. Epub 2013 Jul 2.
Bateman DN, Dear JW, Carroll R, Pettie J, Yamamoto T, Elamin M, Peart L, Dow M, Coyle J, Gray AJ, Dargan P, Wood DM, Eddleston M, Thomas SHL. Impact of reducing the threshold for acetylcysteine treatment in acute paracetamol poisoning: The recent United Kingdom experience. Clinical Toxicology (2014) 52 (8), 868-872
Bateman DN, Pettie J, Carroll R, Dow M, Coyle J, Cranfield K, Gray AJ, Hook C, Sandilands E, Veiraiah A, Webb DJ, Dear JW, Eddleston M. Effects of initial acetylcysteine infusion rates on adverse reactions in paracetamol overdose: A cohort study. CLINICAL TOXICOLOGY (2014) 52 (4), 303-303, 2014
Bateman DN, Carroll R, Pettie J, Yamamoto T, Elamin ME, Peart L, Dow M, Coyle J, Cranfield KR, Hook C, Sandilands EA, Veiriaiah A, Webb DJ, Gray A, Dargan PI, Wood DM, Thomas SH, Dear JW, Eddleston M. Effect of the UK’s Revised Paracetamol Poisoning Management Guidelines on Admissions, Adverse Reactions, and Costs of Treatment. Br J Clin Pharmacol. 2014 Mar 26. doi: 10.1111/bcp.12362. [Epub ahead of print]
Bateman DN, Dear JW, Thanacoody HK, Thomas SH, Eddleston M, Sandilands EA, Coyle J, Cooper JG, Rodriguez A, Butcher I, Lewis SC, Vliegenthart AD, Veiraiah A, Webb DJ, Gray A. Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. Lancet. 2014 Feb 22;383(9918):697-704. doi: 10.1016/S0140-6736(13)62062-0. Epub 2013 Nov 28.
Dear JW, Antoine DJ, Starkey-Lewis P, Platt V, Coyle J, Masson M, Thanacoody RH, Gray AJ, Webb DJ, J Moggs, Bateman DN, Goldring C, Park K. Mechanistic biomarkers provide early and sensitive detection of paracetamol-induced acute liver injury at first presentation to hospital.CLINICAL TOXICOLOGY (2013) 51 (4), 255-255, 2013
Gray AJ, Dear JW, Thanacoody RH, Thomas SH S, Eddleston M, Sandilands E, Coyle J, Cooper J, Rodriguez A, Butcher I, Lewis S, Vliegenthart A, Veiraiah A, Webb DJ, Bateman DN. Reducing adverse effects from intravenous n-acetylcysteine treatment of paracetamol poisoning: principal results of the Scottish and Newcastle antiemetic pre-treatment for paracetamol poisoning (SNAP) randomised controlled trial. Emergency Medicine Journal (2013) 30 (10), 867-868
Thanacoody HK, Gray A, Dear JW, Coyle J, Sandilands EA, Webb DJ, Lewis S, Eddleston M, Thomas SH, Bateman DN. Scottish and Newcastle antiemetic pre-treatment for paracetamol poisoning study (SNAP). BMC Pharmacol Toxicol. 2013 Apr 4;14:20. doi: 10.1186/2050-6511-14-20.
Assisting in identifying patients with Humeral shaft fractures in the ED by screening.
Giving patient information sheets to introduce the study, so patient has had adequate time to read and make decision about going into the trial before going to the fracture clinic.
People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.
Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.
KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.